ABOUT US
Under Development
Managed by a Professional Team Over 20 Years of Experience in Digital Biotechnology
R&D and Investment Funds Raised Towards Development & Commercialization of the World's First Mitochondrial Therapy
Our mission is to revolutionize healthcare
by harnessing the untapped potential of mitochondria.
We are committed to advancing mitochondria-based technologies to develop innovative therapies for rare, chronic, and hard-to-treat diseases—improving quality of life through science-driven breakthroughs.
OUR VALUES
We foster innovation to push the boundaries of biotechnology, embrace collaboration to work across disciplines and partners, harness advanced technology to solve unmet medical needs, and uphold rigor in every process to ensure excellence and trust.
These values are embedded in everything we do—every discovery, every trial, every breakthrough.
Applying the unique characteristics of mitochondria and proprietary technology platform, PAEAN is developing a first-in-class mitochondria-based pharmaceutical product that has a large potential to treat various rare diseases and cancer.
MILESTONE
Seoul National University Hospital
2018 UNTIL NOW
Korea Investment Partners with KRW 1.5 B
JUN 2018
Korea Investment Partners, Hana Ventures, Timefolio with KRW 6 B
JUN 2019
Korea Investment Partners, Hana Ventures Timefolio with KRW 4.5 B
JUN 2021
Jung-gu, Seoul
JUN 2021
World-first allogenic mitochondria as therapeutic agent
JUN 2021
MOU with Soonchunhyang University Medical Center and SIMS
SEP 2021 Until Now
Daol Investment, Hana Ventures, Timefolio, IMM Investment with KRW 7 B
SEP 2022
MOU with YiPSCELL
DEC 2022 Until Now
MAR 2025
JUL 2025
PAEAN protects its innovations through a growing portfolio of patents, including granted and pending filings across Korea, the United States, and other major markets.
International Patent Applications
Korean Patents Granted
Total Global
Filings
We Collaborate with leading research institutions, hospitals, and global investors to Accelerate the Development of next-generation mitochondrial therapies.